AP-SA02

AXP000221.1 · Phage therapy

Platform
phage cocktail (non-engineered)
Originator
Armata Pharmaceuticals
Sponsor
Armata Pharmaceuticals

Names

NameTypeSource
AP-SA02preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
Staphylococcus aureus bacteriophage (cocktail)
Replication
replicating
Route
intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05184764Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus BacteremiaCompletedPhase 1/22022-04-262024-11-0756Bacteremia; Bacteremia Due to Staphylococcus Aureus; Bacteremia Staph; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 43010175Engineered bacteriophages as precision antimicrobials against multidrug-resistant ESKAPE pathogens: molecular engineering strategies, clinical translation, and the crystallizing global regulatory landscape.Future science OA2026name in abstract: AP-SA02

Notes

Intravenous multi-phage product against Staphylococcus aureus bacteraemia. Phase 1b/2a diSArm NCT05184764, topline reported 2025. A later product than AB-SA01 and entered separately.

How to cite

AP-SA02 (AXP000221.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000221.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.